Methods and compositions for treating malignant tumors associated with KRAS mutation
AssigneeNitto Denko Corporation
InventorsKenjirou Minomi, Jihua Liu, Li Wang, Bharat Majeti, Roger Adami, Wenbin Ying
Life of this patent
Estimating the term…
Abstract
This invention provides methods and compositions for preventing, treating or ameliorating one or more symptoms of a malignant tumor associated with KRAS mutation in a mammal in need thereof, by identifying a tumor cell in the mammal, the tumor cell comprising at least one of: (i) a mutation of the KRAS gene, and (ii) an aberrant expression level of KRAS protein; and administering to the mammal a therapeutically effective amount of a composition comprising one or more RNAi molecules that are active in reducing expression of GST-π.
Claims27
A pharmaceutical composition for the treatment or therapy of a tumor associated with a mutation in the KRAS gene or overexpression of wild-type KRAS gene, the composition comprising RNAi molecules and pharmaceutically acceptable excipients, wherein the RNAi molecules comprise an antisense strand which comprises SEQ ID NO:
- 184 and a sense strand which comprises SEQ ID NO:
- 158.
A method for preventing, treating or ameliorating one or more symptoms of a malignant tumor associated with KRAS mutation in a mammal in need thereof, the method comprising:
- identifying a tumor cell in the mammal, the tumor cell comprising at least one of:
- (i) a mutation of the KRAS gene, and (ii) an aberrant expression level of KRAS protein;
- and
- administering to the mammal a therapeutically effective amount of a composition comprising one or more RNAi molecules that are active in reducing expression of GST-π, and wherein the RNAi molecules comprise an antisense strand which comprises SEQ ID NO:
- 184 and a sense strand which comprises SEQ ID NO:
- 18.
Dependencies are inferred from the claim text.